Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THR-1442 (Bexagliflozin) vs Dapagliflozin in T2DM on Metformin
NCT05159882Phase 3Unknown
- Sponsor
- Newsoara Biopharma
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Newsoara Biopharma. Primary endpoint: Change From Baseline in Hemoglobin A1c at 24 weeks. Status: unknown.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05159882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159882.